FDA cancer-trial agenda puts patient-reported outcomes beyond treatment in focus

News date: 2026-10-16
Checked at: 2026-10-16T02:25:46.720Z (UTC)

FDA’s Oncology Center of Excellence made patients’ experiences beyond the immediate treatment period a central question in the agenda for its October 15, 2026 virtual cancer-trials workshop. The U.S. event’s published program addresses whether existing measures capture what matters to people living longer with cancer.

Three key points

• The agency’s 11th annual workshop was scheduled for October 15, 1–4 p.m. ET.
• The program includes patient co-design, longer survivorship and more frequent data collection.
• An agenda describes issues for discussion; it does not establish new treatment benefits or trial requirements.

Looking beyond the acute treatment window

The program describes gaps that may arise as therapies and survivorship change. Its two panel sessions were designed with patient advocates making up most panelists. The emphasis is on what research measures capture, rather than announcing a new cancer medicine.

Technology is part of the discussion

FDA lists electronic reporting, wearables and AI-assisted monitoring among topics for exploration. The published agenda provides no independent performance findings for those tools and no final conclusions from the workshop.

Sources

• FDA Oncology Center of Excellence — original workshop program — Event program for October 15, 2026; checked October 16

Image credits

This editorial collage combines the credited real photograph and conceptual ink drawings. Archive photographs are dated; the cover is an illustration, not an event photograph. topic.red; U.S. Food and Drug Administration / Wikimedia Commons — Public domain — U.S. government work